Oppenheimer Out Positive On BioLineRx, Says That 38% Response Rate Reported At ASH 2016 May Now Be Translating Into Survival Benefit For Patients; Believes 11.1 Median Overall Survival Observed In Cohort Is Respectable; Reiterates Outperform and $3 PT